Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01488552 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
A Phase 1 study of Stage IV Pancreatic Cancer, sponsored by Pancreatic Cancer Research Team.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT01488552: Completed Phase 1 study of Stage IV Pancreatic Cancer, sponsored by Pancreatic Cancer Research Team.
NCT01488552 is a Phase 1 study of Stage IV Pancreatic Cancer that has completed, run by Pancreatic Cancer Research Team. The registered enrollment target is 60 participants, below the 75-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (20% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01488552, a Phase 1 study of Stage IV Pancreatic Cancer, has completed, sponsored by Pancreatic Cancer Research Team.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
The Investigators in the PCRT team have developed a therapeutic regimen which attacks both the tumor compartment and the stromal compartment of pancreatic cancer and induces complete responses in a small percentage of patients with advanced stage IV pancreatic cancer.
Primary Outcome
The primary objectives of this study are to relentlessly pursue treatment for 34 individual patients with Stage IV pancreatic cancer to obtain: • The complete response rate (as defined by a complete metabolomic response (CMR) of SUV normalization from baseline, OR a complete response on CT scan using a modified RECIST criteria and CA 19-9 (or CA 125, CEA, or PAM4 if not expressers of CA 19-9) down to normal limits (from at least \> 2X ULN).
Conditions Studied
Interventions
- DRUG Metformin
- DRUG Gemcitabine
- DRUG nab-paclitaxel
- DRUG FOLFIRINOX
- GENETIC Immunohistochemistry (IHC) Analysis
Study Locations (5)
Washington
- Virginia Mason Medical Center - Seattle
- Evergreen Hematology and Oncology - Spokane
Arizona
- TGen Clinical Research Services (TCRS) - Scottsdale
California
- Disney Family Cancer Center - Burbank
Minnesota
- Virginia Piper Cancer Institute (VPCI) - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2011-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 1 |
What the finished NCT01488552 record still lists
NCT01488552 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 75-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (20% lower).
The record links to 1 condition, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 5 interventions - of which Metformin is the first listed.
NCT01488552 lists 5 locations in 4 states (Washington, Arizona, California).
Frequently Asked Questions
What is clinical trial NCT01488552 about?
NCT01488552 is a clinical study titled "Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer". The Investigators in the PCRT team have developed a therapeutic regimen which attacks both the tumor compartment and the stromal compartment of pancreatic cancer and induces complete responses in a small percentage of patients with advanced stage IV pancreatic cancer.
What is the current status of trial NCT01488552?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2011-11. Estimated completion is 2016-08.
What conditions does trial NCT01488552 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer.
What interventions are being tested in trial NCT01488552?
The interventions under investigation include: Metformin (DRUG), Gemcitabine (DRUG), nab-paclitaxel (DRUG), FOLFIRINOX (DRUG), Immunohistochemistry (IHC) Analysis (GENETIC).
Who is sponsoring clinical trial NCT01488552?
This trial is sponsored by Pancreatic Cancer Research Team, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01488552 being conducted?
This trial has 5 study locations across Arizona, California, Minnesota, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01488552's enrollment target sits among peer trials
60 5th of 15 higher than 11 of 15 other Stage IV Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
ACTIVE NOT RECRUITING · Phase 1
-
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer
COMPLETED · Phase 1
-
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
COMPLETED · Phase 1
-
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
COMPLETED · Phase 1
-
Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors, Pancreatic Cancer and Biliary Cancers
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia